Volume 1, Issue 2, July 2022

					View Volume 1, Issue 2, July 2022
  • Immunotherapy in Hodgkin lymphoma: Current and evolving roles
  • Tailoring therapy in Waldenström Macroglobulinemia
  • Multiple myeloma management: What comes after lenalidomide-based therapy?
  • Chimeric antigen receptor T-cell therapy for relapsed and refractory large B-cell lymphoma: A Canadian perspective
  • With great power comes great responsibility: Managing side effects of novel treatments in chronic lymphocytic leukemia (CLL)
Published: 2022-07-01